Pharmacokinetics-Pharmacodynamics Modeling and Evaluation of Tumor Response to Bortezomib Proteasome Inhibitor in Waldenstrom Macroglobulinemia.

Munir, Anum; Fazal, Sahar; Bhatti, Aamer Iqbal; Sajjad, Bilawal

Munir, Anum; Fazal, Sahar; Bhatti, Aamer Iqbal; Sajjad, Bilawal.

Afiliação

Munir A; School of Biosciences, University of Kent, Canterbury.
Fazal S; Department of Applied Biology, The London College UCK, London.
Bhatti AI; Department of Bioinformatics and Biosciences, Faculty of Health, and Life Sciences.
Sajjad B; Department of Electrical Engineering, Capital University of Science and Technology, Islamabad.

Am J Clin Oncol ; 46(4): 150-160, 2023 04 01.

Article em En | MEDLINE | ID: mdl-36808095

Assuntos

Inibidores de Proteassoma; Macroglobulinemia de Waldenstrom; Humanos; Bortezomib/farmacologia; Bortezomib/uso terapêutico; Inibidores de Proteassoma/farmacologia; Inibidores de Proteassoma/uso terapêutico; Macroglobulinemia de Waldenstrom/tratamento farmacológico; Macroglobulinemia de Waldenstrom/patologia; Recidiva Local de Neoplasia/tratamento farmacológico; Rituximab/farmacologia; Rituximab/uso terapêutico

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Macroglobulinemia de Waldenstrom / Inibidores de Proteassoma Limite: Humans Idioma: En Revista: Am J Clin Oncol Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google